Heterogeneity of Low-Density Lipoprotein Particle Number in Patients With Type 2 Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl

American Journal of Cardiology

Volumn 98, Issue 12, 2006, Pages 1599-1602

  Cromwell, William C ^a,b   Otvos, James D ^c  

^a Presbyterian Center for Preventive Cardiology   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c LIPOSCIENCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; PARTICLE SIZE; TRIGLYCERIDES;

EID: 35048833627     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.07.036     Document Type: Article

References (20)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361 (2003) 2005-2016
2. Davidson M.H. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 96 suppl (2005) 3K-13K
3. Cromwell W.C., and Otvos J.D. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6 (2004) 381-387
4. Sniderman A.D., Furberg C.D., Keech A., Roeters van Lennep J.E., Frohlich J., Jungner I., and Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 361 (2003) 777-780
5. Barter P.J., Ballantyne C.M., Carmena R., Castro Cabezas M., Chapman M.J., Couture P., De Graaf J., Durrington P.N., Faergeman O., Frohlich J., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
6. Otvos J.D., Jeyarajah E.J., and Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90 suppl (2002) 22i-29i
7. Stein E.A., Sniderman A., and Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 96 suppl (2005) 36K-43K
8. Kathiresan S., Otvos J.D., Sullivan L.M., Keyes M.J., Schaefer E.J., Wilson P.W., D'Agostino R.B., Vasan R.S., and Robins S.J. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113 (2006) 20-29
9. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., Bloomfield H.E., and Robins S.J. LDL and HDL particle subclasses predict coronary events and are changed favorably by gemfibrozil therapy in the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 113 (2006) 1556-1563
10. Grundy S.M., Cleeman J.I., Merz C.N.B., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
11. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-508
12. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48 (2002) 171-180
13. Festa A., Williams K., Hanley A.J.G., Otvos J.D., Goff D.C., Wagenknecht L.E., and Haffner S.M. Nuclear magnetic resonance (NMR) lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 111 (2005) 3465-3472
14. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, O'Leary DH, Saad MF, Tsai MY, Sharrett AR. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2006. In press.
15. NCEP Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
16. Berneis K.K., and Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002) 1363-1379
17. Garvey W.T., Kwon S., Zheng D., Shaughnessy S., Wallace P., Hutto A., Pugh K., Jenkins A.J., Klein R.L., and Liao Y. The effects of insulin resistance and type 2 diabetes mellitus on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-462
18. O'Keefe Jr. J.H., Cordain L., Harris W.H., Moe R.M., and Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J Am Call Cardiol 43 (2004) 2142-2146
19. Rosenson R., and Lloyd-Jones D. Critical appraisal of revised cholesterol guidelines for the very high-risk patient. Expert Rev Cardiovasc Ther 3 (2005) 1-7
20. Topol E.J. Intensive statin therapy-a sea change in cardiovascular prevention. N Engl J Med 350 (2004) 1562-1564